Shenhong Qu

Dr. Shenhong Qu

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2024 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
GWGang Wang
Gang Wang
XZXiaosu Zou
Xiaosu Zou
QCQicong Chen
Qicong Chen
WNWenqian Nong
Wenqian Nong
WMWeiwei Miao
Weiwei Miao
SQShenhong Qu
Shenhong Qu
Lactylation, an emerging post-translational modification, plays a pivotal role in the initiation and progression of digestive system tumors. This study presents a comprehensive review of lactylation in digestive system tumors, underscoring its critical involvement in tumor development and progression. By focusing on metabolic reprogramming, modulation of the tumor microenvironment, and the molecular mechanisms regulating tumor progression, the potential of targeting lactylation as a therapeutic strategy is highlighted. The research reveals that lactylation participates in gene expression regulation and cell signaling by affecting the post-translational states of histones and non-histone proteins, thereby influencing metabolic pathways and immune evasion mechanisms in tumor cells. Furthermore, this study assesses the feasibility of lactylation as a therapeutic target, providing insights for clinical treatment of gastrointestinal cancers. Future research should concentrate on elucidating the mechanisms of lactylation, developing efficient lactylation inhibitors, and validating their therapeutic efficacy in clinical trials, which could transform current cancer treatment and immunotherapy approaches. In summary, this review emphasizes the crucial role of lactylation in tumorigenesis and progression through a detailed analysis of its molecular mechanisms and clinical significance.

1 May 2020 in Cancer Letters
Verified
Journal Article
Closed access
JWJiazhang Wei
Jiazhang Wei
JYJiaxiang Ye
Jiaxiang Ye
YLYue Luo
Yue Luo
JWJingjin Weng
Jingjin Weng
QHQian He
Qian He
JZJinyan Zhang
Jinyan Zhang

1 January 2021 in Bioengineered
Verified
Journal Article
Open access
FLFei Liu
Fei Liu
JWJiazhang Wei
Jiazhang Wei
YHYanrong Hao
Yanrong Hao
JLJiao Lan
Jiao Lan
WLWei Li
Wei Li
SQShenhong Qu
Shenhong Qu
Our previous studies have elucidated a possible connection between long intergenic non-protein coding RNA 2570 (LINC02570) and nasopharyngeal carcinoma (NPC). However, the precise mechanism by which LINC02570 promotes NPC remains unknown. We used quantitative polymerase chain reaction (qPCR) to detect LINC02570 expression in nasopharyngeal cell lines, NPC tissues, and chronic rhinitis tissues. Subcellular LINC02570 localization was confirmed by fluorescence in situ hybridization (FISH). The effects of LINC02570 stable knockdown and overexpression on viabillity, proliferation, migration, and invasion were analyzed using 3-(4,5-Dimethyl-2-Thiazolyl)-2,5-Diphenyl-2-H-Tetrazolium bromide (MTT), a colorimetric focus-formation assay, a wound healing assay, and transwell assays. RNA crosstalk analysis in silico predicted microRNA-4649-3p (miR-4649-3p) binding to LINC02570 or sterol regulatory element binding transcription factor 1 (SREBF1). A dual luciferase reporter assay was used to confirm potential interactions. Sterol regulatory element binding protein 1 (SREBP1) and fatty acid synthase (FASN) expression were detected by western blotting. The results suggest that LINC02570 is upregulated in late clinical stage NPC patients, and promotes NPC progression by adsorbing miR-4649-3p to up-regulate SREBP1 and FASN. This study elucidates a potential chemotherapeutic target involved in lipid metabolism in NPC.

27 November 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JWJing‐Jin Weng
Jing‐Jin Weng
JWJia‐Zhang Wei
Jia‐Zhang Wei
MLMin Li
Min Li
JLJin‐Long Lu
Jin‐Long Lu
YQYang‐Da Qin
Yang‐Da Qin
SQShenhong Qu
Shenhong Qu
Purpose: To investigate the clinical characteristics of nasopharyngeal carcinoma (NPC) and a concomitant hepatitis B virus (HBV) infection, as well as the potential effects of HBV infection and antiviral therapy on prognosis.Methods: We conducted a retrospective chart review of all NPC patients from December 2010 to December 2014. After collecting medical records and conducting follow‐ups on patients, a total of 876 eligible NPC patients were included. For each patient, medical records were reviewed. Factors predictive of outcome were compared using the log‐rank test and Cox regression analysis.Results: Among the 876 participants, 106 (12.1%) patients were HBV‐infected patients. The hepatitis B surface antigen‐positive [HBsAg(+)] group had a lower CD4+ T cell count than the HBsAg(−) group (P = .048). Among patients with stage I/II NPC, 5‐year overall survival (OS), disease‐free survival (DFS), relapse‐free survival, and distant metastasis‐free survival (DMFS) of the HBsAg(+) group were 82.5%, 70.7%, 87.7%, and 76.6%, respectively, whereas those of the HBsAg(−) group were 91.4%, 86.0%, 93.8%, and 92.1%, respectively. Statistically significant differences in OS, DFS, and DMFS existed between both groups (P = .017, .018, and .004, respectively). The multivariate analysis indicated that HBsAg status and N stage are independent risk factors affecting OS, DFS, and DMFS of NPC patients. A statistically significant difference in 5‐year DMFS existed between the antivirus (90.0%) and no‐antivirus groups (70.0%) (P = .043).Conclusions: Hepatitis B virus infection is an independent risk factor for early stage NPC, which may be associated with its reduced immune functions compared to the HBsAg(−) group. Anti‐HBV treatment may improve the prognosis of HBV‐infected NPC patients.

1 September 2021 in Cancer Letters
Verified
Journal Article
Closed access
JWJiazhang Wei
Jiazhang Wei
YDYayan Deng
Yayan Deng
JYJiaxiang Ye
Jiaxiang Ye
YLYue Luo
Yue Luo
JWJingjin Weng
Jingjin Weng
SQShenhong Qu
Shenhong Qu

13 May 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
YWYong-Li Wang
Yong-Li Wang
DRDan Ren
Dan Ren
JLJin-Long Lu
Jin-Long Lu
HJHe Jiang
He Jiang
JWJia-Zhang Wei
Jia-Zhang Wei
SQShenhong Qu
Shenhong Qu